These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

322 related items for PubMed ID: 23848591

  • 1. Morphologic changes and visual outcomes in resolved central serous chorioretinopathy treated with ranibizumab.
    Ozdemir O, Erol MK.
    Cutan Ocul Toxicol; 2014 Jun; 33(2):122-6. PubMed ID: 23848591
    [Abstract] [Full Text] [Related]

  • 2. Outer nuclear layer thickness at the fovea determines visual outcomes in resolved central serous chorioretinopathy.
    Matsumoto H, Sato T, Kishi S.
    Am J Ophthalmol; 2009 Jul; 148(1):105-10.e1. PubMed ID: 19327740
    [Abstract] [Full Text] [Related]

  • 3. [Morphologic changes in acute central serous chorioretinopathy evaluated by spectral domain optical coherence tomography].
    Yu H, Xia GY, Gao MH, Yu J, Zhang YY.
    Zhonghua Yan Ke Za Zhi; 2011 Jun; 47(6):508-15. PubMed ID: 21914265
    [Abstract] [Full Text] [Related]

  • 4. Association between foveal microstructure and visual outcome in age-related macular degeneration.
    Shin HJ, Chung H, Kim HC.
    Retina; 2011 Sep; 31(8):1627-36. PubMed ID: 21606888
    [Abstract] [Full Text] [Related]

  • 5. Three-dimensional imaging of the foveal photoreceptor layer in central serous chorioretinopathy using high-speed optical coherence tomography.
    Ojima Y, Hangai M, Sasahara M, Gotoh N, Inoue R, Yasuno Y, Makita S, Yatagai T, Tsujikawa A, Yoshimura N.
    Ophthalmology; 2007 Dec; 114(12):2197-207. PubMed ID: 17507096
    [Abstract] [Full Text] [Related]

  • 6. Morphologic changes in the outer layer of the detached retina in rhegmatogenous retinal detachment and central serous chorioretinopathy.
    Maruko I, Iida T, Sekiryu T, Saito M.
    Am J Ophthalmol; 2009 Mar; 147(3):489-494.e1. PubMed ID: 19058780
    [Abstract] [Full Text] [Related]

  • 7. Correlation of foveal microstructural changes with vision after anti-vascular endothelial growth factor therapy in age-related macular degeneration.
    Shin HJ, Chung H, Kim HC.
    Retina; 2013 May; 33(5):964-70. PubMed ID: 23348865
    [Abstract] [Full Text] [Related]

  • 8. The relationship between foveal outer nuclear layer thickness in the active and resolved phases of central serous chorioretinopathy treated with half-dose photodynamic therapy.
    Yu J, Lei Y, Chang Q, Xu G, Ye X, Li L, Jiang C.
    BMC Ophthalmol; 2019 Mar 29; 19(1):84. PubMed ID: 30922273
    [Abstract] [Full Text] [Related]

  • 9. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment.
    Reznicek L, Cserhati S, Seidensticker F, Liegl R, Kampik A, Ulbig M, Neubauer AS, Kernt M.
    Acta Ophthalmol; 2013 Nov 29; 91(7):e529-36. PubMed ID: 23647578
    [Abstract] [Full Text] [Related]

  • 10. Foveal microstructure and visual acuity in surgically closed macular holes: spectral-domain optical coherence tomographic analysis.
    Wakabayashi T, Fujiwara M, Sakaguchi H, Kusaka S, Oshima Y.
    Ophthalmology; 2010 Sep 29; 117(9):1815-24. PubMed ID: 20472291
    [Abstract] [Full Text] [Related]

  • 11. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH, Heo J, Kim C, Kim TW, Shin JY, Lee JY, Song SJ, Park TK, Moon SW, Chung H.
    Ophthalmology; 2014 Feb 29; 121(2):558-65. PubMed ID: 24268858
    [Abstract] [Full Text] [Related]

  • 12. Early changes in foveal thickness in eyes with central serous chorioretinopathy.
    Hata M, Oishi A, Shimozono M, Mandai M, Nishida A, Kurimoto Y.
    Retina; 2013 Feb 29; 33(2):296-301. PubMed ID: 23023530
    [Abstract] [Full Text] [Related]

  • 13. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V, Vysloužilová D, Uher M.
    Semin Ophthalmol; 2018 Feb 29; 33(5):690-699. PubMed ID: 29252091
    [Abstract] [Full Text] [Related]

  • 14. Elongation of photoreceptor outer segment in central serous chorioretinopathy.
    Matsumoto H, Kishi S, Otani T, Sato T.
    Am J Ophthalmol; 2008 Jan 29; 145(1):162-168. PubMed ID: 18028861
    [Abstract] [Full Text] [Related]

  • 15. Intravitreal ranibizumab for macular edema secondary to retinal vein occlusion.
    Kim M, Yu SY, Kim ES, Bae SH, Park JH, Yu HG, Kwak HW.
    Ophthalmologica; 2012 Jan 29; 227(3):132-8. PubMed ID: 22212151
    [Abstract] [Full Text] [Related]

  • 16. Predictors of short-term visual outcome after anti-VEGF therapy of macular edema due to central retinal vein occlusion.
    Wolf-Schnurrbusch UE, Ghanem R, Rothenbuehler SP, Enzmann V, Framme C, Wolf S.
    Invest Ophthalmol Vis Sci; 2011 May 18; 52(6):3334-7. PubMed ID: 21087958
    [Abstract] [Full Text] [Related]

  • 17. Correlation of spectral domain optical coherence tomography findings and visual acuity in central serous chorioretinopathy.
    Yalcinbayir O, Gelisken O, Akova-Budak B, Ozkaya G, Gorkem Cevik S, Yucel AA.
    Retina; 2014 Apr 18; 34(4):705-12. PubMed ID: 24100708
    [Abstract] [Full Text] [Related]

  • 18. Intravitreal anti-vascular endothelial growth factor versus observation in acute central serous chorioretinopathy: one-year results.
    Park SU, Lee SJ, Kim M.
    Korean J Ophthalmol; 2014 Aug 18; 28(4):306-13. PubMed ID: 25120339
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.